Adjuvant Abemaciclib + Endocrine Therapy for HR+, HER2- High-Risk eBC: Results From a Preplanned monarchE OS Interim Analysis, Including 5-Year Efficacy Outcomes

1,469 views
December 4, 2023
0 Comments
Login to view comments. Click here to Login